JP2018527336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527336A5 JP2018527336A5 JP2018506432A JP2018506432A JP2018527336A5 JP 2018527336 A5 JP2018527336 A5 JP 2018527336A5 JP 2018506432 A JP2018506432 A JP 2018506432A JP 2018506432 A JP2018506432 A JP 2018506432A JP 2018527336 A5 JP2018527336 A5 JP 2018527336A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- indol
- phenyl
- sulfonyl
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- -1 6-fluoro-1H-indol-3-yl Chemical group 0.000 claims 29
- 229910052736 halogen Inorganic materials 0.000 claims 19
- 150000002367 halogens Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 9
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 3
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 3
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- LXHXFLKPMOIAAG-DLBZAZTESA-N (3R,4S)-4-fluoro-1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpyrrolidin-3-amine Chemical compound F[C@@H]1[C@@H](CN(C1)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(=CC=C12)F)N LXHXFLKPMOIAAG-DLBZAZTESA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- USVDVLNQDDGINX-UHFFFAOYSA-N [1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperazin-2-yl]methanol Chemical compound OCC1CNCCN1S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(F)=CC=C12 USVDVLNQDDGINX-UHFFFAOYSA-N 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- BEFLCWOSSCEMOC-MTFMMBMASA-N (2R,3R,4S,5S)-5-fluoro-1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-2-(hydroxymethyl)piperidine-3,4-diol Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](F)CN1S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 BEFLCWOSSCEMOC-MTFMMBMASA-N 0.000 claims 1
- DCHHDRUOBFRHMA-FHWLQOOXSA-N (2S,3S,4S)-1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-2-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound OC[C@H]1[C@H](O)[C@@H](O)CN1S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 DCHHDRUOBFRHMA-FHWLQOOXSA-N 0.000 claims 1
- ZVXBJCWWVUKJDZ-CQSZACIVSA-N (3R)-1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpyrrolidin-3-ol Chemical compound O[C@@H]1CCN(C1)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(F)=CC=C12 ZVXBJCWWVUKJDZ-CQSZACIVSA-N 0.000 claims 1
- WLLIXOIHPQOJOZ-RTBURBONSA-N (3R,4R)-1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperidine-3,4-diol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1C[C@H]([C@@H](CC1)O)O WLLIXOIHPQOJOZ-RTBURBONSA-N 0.000 claims 1
- DRDFZHHEBIDCJX-QZTJIDSGSA-N (3R,4R)-1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpyrrolidine-3,4-diol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1C[C@H]([C@@H](C1)O)O DRDFZHHEBIDCJX-QZTJIDSGSA-N 0.000 claims 1
- LXHXFLKPMOIAAG-IAGOWNOFSA-N (3R,4R)-4-fluoro-1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpyrrolidin-3-amine Chemical compound F[C@H]1[C@@H](CN(C1)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(=CC=C12)F)N LXHXFLKPMOIAAG-IAGOWNOFSA-N 0.000 claims 1
- DRDFZHHEBIDCJX-HDICACEKSA-N (3R,4S)-1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpyrrolidine-3,4-diol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1C[C@H]([C@H](C1)O)O DRDFZHHEBIDCJX-HDICACEKSA-N 0.000 claims 1
- ZVXBJCWWVUKJDZ-AWEZNQCLSA-N (3S)-1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpyrrolidin-3-ol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1C[C@H](CC1)O ZVXBJCWWVUKJDZ-AWEZNQCLSA-N 0.000 claims 1
- WLLIXOIHPQOJOZ-MOPGFXCFSA-N (3S,4R)-1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperidine-3,4-diol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1C[C@@H]([C@@H](CC1)O)O WLLIXOIHPQOJOZ-MOPGFXCFSA-N 0.000 claims 1
- DRDFZHHEBIDCJX-ROUUACIJSA-N (3S,4S)-1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpyrrolidine-3,4-diol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1C[C@@H]([C@H](C1)O)O DRDFZHHEBIDCJX-ROUUACIJSA-N 0.000 claims 1
- LXHXFLKPMOIAAG-IRXDYDNUSA-N (3S,4S)-4-fluoro-1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpyrrolidin-3-amine Chemical compound F[C@@H]1[C@H](CN(C1)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(=CC=C12)F)N LXHXFLKPMOIAAG-IRXDYDNUSA-N 0.000 claims 1
- MCUULSPCLNTZND-UHFFFAOYSA-N 1-(2-aminoethyl)-4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperazin-2-one Chemical compound NCCN1CCN(CC1=O)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(F)=CC=C12 MCUULSPCLNTZND-UHFFFAOYSA-N 0.000 claims 1
- KZRZHZSIHHHXOU-UHFFFAOYSA-N 1-(3-aminopropyl)-4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperazin-2-one Chemical compound NCCCN1C(CN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(=CC=C12)F)=O KZRZHZSIHHHXOU-UHFFFAOYSA-N 0.000 claims 1
- KPSFBAPMIVIYKY-MRXNPFEDSA-N 1-[(2R)-2,3-dihydroxypropyl]-4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperazin-2-one Chemical compound O[C@H](CN1C(CN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(=CC=C12)F)=O)CO KPSFBAPMIVIYKY-MRXNPFEDSA-N 0.000 claims 1
- KPSFBAPMIVIYKY-INIZCTEOSA-N 1-[(2S)-2,3-dihydroxypropyl]-4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperazin-2-one Chemical compound O[C@@H](CN1C(CN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(=CC=C12)F)=O)CO KPSFBAPMIVIYKY-INIZCTEOSA-N 0.000 claims 1
- XTEXWRBMDKDLBA-UHFFFAOYSA-N 1-[2-(dimethylamino)ethyl]-4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperazin-2-one Chemical compound CN(CCN1C(CN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(=CC=C12)F)=O)C XTEXWRBMDKDLBA-UHFFFAOYSA-N 0.000 claims 1
- YDKROAUMUPAUDN-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperazin-2-one Chemical compound CN(C)CCCN1CCN(CC1=O)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(F)=CC=C12 YDKROAUMUPAUDN-UHFFFAOYSA-N 0.000 claims 1
- VXEAJCMTXUMDSS-UHFFFAOYSA-N 1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-1,4-diazepan-5-one Chemical compound FC1=CC=C2C(NC=C2C2=CC=C(C=C2)S(=O)(=O)N2CCNC(=O)CC2)=C1 VXEAJCMTXUMDSS-UHFFFAOYSA-N 0.000 claims 1
- OYWBDXZZBKJGOD-UHFFFAOYSA-N 1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-3-(2-methylpyrazol-3-yl)pyrrolidin-3-ol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CC(CC1)(O)C1=CC=NN1C OYWBDXZZBKJGOD-UHFFFAOYSA-N 0.000 claims 1
- NRWZKXXYLJNRQD-UHFFFAOYSA-N 1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-3-[(2-methylimidazol-1-yl)methyl]piperidin-3-ol Chemical compound Cc1nccn1CC1(O)CCCN(C1)S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 NRWZKXXYLJNRQD-UHFFFAOYSA-N 0.000 claims 1
- UAAIQIGBIXIRBU-UHFFFAOYSA-N 1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-3-[(2-methylimidazol-1-yl)methyl]pyrrolidin-3-ol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CC(CC1)(O)CN1C(=NC=C1)C UAAIQIGBIXIRBU-UHFFFAOYSA-N 0.000 claims 1
- OCGIPRBQXPZIFF-UHFFFAOYSA-N 1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-3-pyrimidin-4-ylpyrrolidin-3-ol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CC(CC1)(O)C1=NC=NC=C1 OCGIPRBQXPZIFF-UHFFFAOYSA-N 0.000 claims 1
- DSXIECZMNKXIAD-UHFFFAOYSA-N 1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-3-pyrimidin-5-ylpyrrolidin-3-ol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CC(CC1)(O)C=1C=NC=NC=1 DSXIECZMNKXIAD-UHFFFAOYSA-N 0.000 claims 1
- IVBSJRPDKKLIIN-UHFFFAOYSA-N 1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylazetidin-3-ol Chemical compound OC1CN(C1)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(F)=CC=C12 IVBSJRPDKKLIIN-UHFFFAOYSA-N 0.000 claims 1
- ZVXBJCWWVUKJDZ-UHFFFAOYSA-N 1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpyrrolidin-3-ol Chemical compound OC1CCN(C1)S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 ZVXBJCWWVUKJDZ-UHFFFAOYSA-N 0.000 claims 1
- VHMKUTVZSIHDFK-UHFFFAOYSA-N 1-[6-fluoro-3-(4-piperazin-1-ylsulfonylphenyl)indol-1-yl]-3-methylbutan-1-one Chemical compound FC1=CC=C2C(=CN(C2=C1)C(CC(C)C)=O)C1=CC=C(C=C1)S(=O)(=O)N1CCNCC1 VHMKUTVZSIHDFK-UHFFFAOYSA-N 0.000 claims 1
- BENJUIUUDPZNBB-UHFFFAOYSA-N 1-[6-fluoro-3-(4-piperazin-1-ylsulfonylphenyl)indol-1-yl]ethanone Chemical compound FC1=CC=C2C(=CN(C2=C1)C(C)=O)C1=CC=C(C=C1)S(=O)(=O)N1CCNCC1 BENJUIUUDPZNBB-UHFFFAOYSA-N 0.000 claims 1
- JYSQGHFUNZQSDO-UHFFFAOYSA-N 1-[6-fluoro-3-(4-piperazin-1-ylsulfonylphenyl)indol-1-yl]propan-1-one Chemical compound FC1=CC=C2C(=CN(C2=C1)C(CC)=O)C1=CC=C(C=C1)S(=O)(=O)N1CCNCC1 JYSQGHFUNZQSDO-UHFFFAOYSA-N 0.000 claims 1
- AJXIWJLNLFGCBK-UHFFFAOYSA-N 1-[[1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-3-hydroxypiperidin-3-yl]methyl]pyrrolidin-2-one Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CC(CCC1)(O)CN1C(CCC1)=O AJXIWJLNLFGCBK-UHFFFAOYSA-N 0.000 claims 1
- FRXFHAZKMMZLPL-UHFFFAOYSA-N 1-[[1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-3-hydroxypyrrolidin-3-yl]methyl]pyrrolidin-2-one Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CC(CC1)(O)CN1C(CCC1)=O FRXFHAZKMMZLPL-UHFFFAOYSA-N 0.000 claims 1
- SZFVPNNRLKXAGR-UHFFFAOYSA-N 2-(6-fluoro-1H-indol-3-yl)-5-piperazin-1-ylsulfonylbenzonitrile Chemical compound FC1=CC=C2C(=CNC2=C1)C1=C(C#N)C=C(C=C1)S(=O)(=O)N1CCNCC1 SZFVPNNRLKXAGR-UHFFFAOYSA-N 0.000 claims 1
- HMSVNIFIIXMIRW-NSHDSACASA-N 2-(6-fluoro-1H-indol-3-yl)-N-[(2S)-1-hydroxypropan-2-yl]benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=C(C=CC=C1)S(=O)(=O)N[C@H](CO)C HMSVNIFIIXMIRW-NSHDSACASA-N 0.000 claims 1
- RQASTTLPQZDDGH-UHFFFAOYSA-N 2-(aminomethyl)-4-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound NCC1=C(C=CC(=C1)C1=CNC2=CC(=CC=C12)F)S(=O)(=O)N RQASTTLPQZDDGH-UHFFFAOYSA-N 0.000 claims 1
- MXOYHZOAMCWGEC-UHFFFAOYSA-N 2-[1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperidin-4-yl]oxyacetamide Chemical compound NC(=O)COC1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(F)=CC=C12 MXOYHZOAMCWGEC-UHFFFAOYSA-N 0.000 claims 1
- OROZMZALIFOPCY-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-4-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound CN(C)CCC1=C(C=CC(=C1)C1=CNC2=CC(F)=CC=C12)S(N)(=O)=O OROZMZALIFOPCY-UHFFFAOYSA-N 0.000 claims 1
- AVFXXPZJUCNLPZ-UHFFFAOYSA-N 2-[5-(6-fluoro-1H-indol-3-yl)-2-methylsulfonylphenyl]ethanol Chemical compound FC1=CC=C2C(=CNC2=C1)C=1C=CC(=C(C=1)CCO)S(=O)(=O)C AVFXXPZJUCNLPZ-UHFFFAOYSA-N 0.000 claims 1
- SXKGXICGVUDAGZ-UHFFFAOYSA-N 2-[5-(6-fluoro-1H-indol-3-yl)-2-sulfamoylphenyl]-N,N-dimethylacetamide Chemical compound FC1=CC=C2C(=CNC2=C1)C=1C=CC(=C(C=1)CC(=O)N(C)C)S(N)(=O)=O SXKGXICGVUDAGZ-UHFFFAOYSA-N 0.000 claims 1
- SCANDCLWBAULPS-UHFFFAOYSA-N 2-[5-(6-fluoro-1H-indol-3-yl)-2-sulfamoylphenyl]-N-methylacetamide Chemical compound FC1=CC=C2C(=CNC2=C1)C=1C=CC(=C(C=1)CC(=O)NC)S(N)(=O)=O SCANDCLWBAULPS-UHFFFAOYSA-N 0.000 claims 1
- RQODVMGMCIMDRP-UHFFFAOYSA-N 2-[5-(6-fluoro-1H-indol-3-yl)-2-sulfamoylphenyl]acetamide Chemical compound FC1=CC=C2C(=CNC2=C1)C=1C=CC(=C(C=1)CC(=O)N)S(N)(=O)=O RQODVMGMCIMDRP-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- HPMSAGLCIMNKPM-UHFFFAOYSA-N 3,5-dichloro-4-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(C2=CNC3=CC(F)=CC=C23)C(Cl)=C1 HPMSAGLCIMNKPM-UHFFFAOYSA-N 0.000 claims 1
- VPKXRSVFZMPLOX-UHFFFAOYSA-N 3-(3,5-dichloro-4-piperazin-1-ylsulfonylphenyl)-6-fluoro-1H-indole Chemical compound ClC=1C=C(C=C(C=1S(=O)(=O)N1CCNCC1)Cl)C1=CNC2=CC(=CC=C12)F VPKXRSVFZMPLOX-UHFFFAOYSA-N 0.000 claims 1
- QBFIFTWGUYTCTG-UHFFFAOYSA-N 3-(3,5-difluoro-4-piperazin-1-ylsulfonylphenyl)-6-fluoro-1H-indole Chemical compound FC=1C=C(C=C(C=1S(=O)(=O)N1CCNCC1)F)C1=CNC2=CC(=CC=C12)F QBFIFTWGUYTCTG-UHFFFAOYSA-N 0.000 claims 1
- BAOKAVUKWSTFEY-UHFFFAOYSA-N 3-(3,5-dimethyl-4-piperazin-1-ylsulfonylphenyl)-6-fluoro-1H-indole Chemical compound CC=1C=C(C=C(C=1S(=O)(=O)N1CCNCC1)C)C1=CNC2=CC(=CC=C12)F BAOKAVUKWSTFEY-UHFFFAOYSA-N 0.000 claims 1
- WEGUJRJJGFBAPY-UHFFFAOYSA-N 3-(3-chloro-4-piperazin-1-ylsulfonylphenyl)-6-fluoro-1H-indole Chemical compound ClC=1C=C(C=CC=1S(=O)(=O)N1CCNCC1)C1=CNC2=CC(=CC=C12)F WEGUJRJJGFBAPY-UHFFFAOYSA-N 0.000 claims 1
- URCMRVNRPIKAEJ-UHFFFAOYSA-N 3-(4-chloro-3-piperazin-1-ylsulfonylphenyl)-6-fluoro-1H-indole Chemical compound ClC1=C(C=C(C=C1)C1=CNC2=CC(=CC=C12)F)S(=O)(=O)N1CCNCC1 URCMRVNRPIKAEJ-UHFFFAOYSA-N 0.000 claims 1
- RQOUGWJYRKVEMQ-UHFFFAOYSA-N 3-(4-piperazin-1-ylsulfonylphenyl)-1H-indole Chemical compound N1(CCNCC1)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC=CC=C12 RQOUGWJYRKVEMQ-UHFFFAOYSA-N 0.000 claims 1
- BGTGVJSWXXJTBQ-UHFFFAOYSA-N 3-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C=1C=C(C=CC=1)S(=O)(=O)N BGTGVJSWXXJTBQ-UHFFFAOYSA-N 0.000 claims 1
- VDXFXOOVWIKTGE-OKILXGFUSA-N 3-[4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]sulfonylphenyl]-6-fluoro-1H-indole Chemical compound C[C@H]1CN(C[C@@H](C)N1)S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 VDXFXOOVWIKTGE-OKILXGFUSA-N 0.000 claims 1
- VDXFXOOVWIKTGE-KBPBESRZSA-N 3-[4-[(3S,5S)-3,5-dimethylpiperazin-1-yl]sulfonylphenyl]-6-fluoro-1H-indole Chemical compound C[C@H]1CN(C[C@H](C)N1)S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 VDXFXOOVWIKTGE-KBPBESRZSA-N 0.000 claims 1
- JYIAWOUNEVBZIX-UHFFFAOYSA-N 3-[[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-methylamino]propanamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N(C)CCC(=O)N JYIAWOUNEVBZIX-UHFFFAOYSA-N 0.000 claims 1
- UKYPNXUVLRQSOI-UHFFFAOYSA-N 3-[[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylamino]-N,N-dimethylpropanamide Chemical compound CN(C)C(=O)CCNS(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 UKYPNXUVLRQSOI-UHFFFAOYSA-N 0.000 claims 1
- AONHZBQGVYQNPG-UHFFFAOYSA-N 3-[[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylamino]-N-methylpropanamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)NCCC(=O)NC AONHZBQGVYQNPG-UHFFFAOYSA-N 0.000 claims 1
- COYYCOKOWRXHQU-UHFFFAOYSA-N 3-chloro-4-(6-fluoro-1H-indol-3-yl)-N-(2-hydroxyethyl)benzenesulfonamide Chemical compound ClC=1C=C(C=CC=1C1=CNC2=CC(=CC=C12)F)S(=O)(=O)NCCO COYYCOKOWRXHQU-UHFFFAOYSA-N 0.000 claims 1
- RARWAEUZNOSPIV-UHFFFAOYSA-N 3-chloro-4-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound ClC=1C=C(C=CC=1C1=CNC2=CC(=CC=C12)F)S(=O)(=O)N RARWAEUZNOSPIV-UHFFFAOYSA-N 0.000 claims 1
- PCVGKZDRSRYQKZ-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-2-(2,2,2-trifluoroethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=C(CC(F)(F)F)C=C(C=C1)C1=CNC2=CC(F)=CC=C12 PCVGKZDRSRYQKZ-UHFFFAOYSA-N 0.000 claims 1
- XGHKTBAHALQXCV-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-2-(2-hydroxyethyl)benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC(=C(C=C1)S(=O)(=O)N)CCO XGHKTBAHALQXCV-UHFFFAOYSA-N 0.000 claims 1
- ACNQFWLFTZTHMM-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-2-(hydroxymethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=C(CO)C=C(C=C1)C1=CNC2=CC(F)=CC=C12 ACNQFWLFTZTHMM-UHFFFAOYSA-N 0.000 claims 1
- IUHLEFYHOHEKSI-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-2-[2-(methylamino)ethyl]benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC(=C(C=C1)S(=O)(=O)N)CCNC IUHLEFYHOHEKSI-UHFFFAOYSA-N 0.000 claims 1
- RDEMMWYBNGQWTB-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-(2-hydroxy-2-pyrazin-2-ylethyl)-N-methylbenzenesulfonamide Chemical compound CN(CC(O)c1cnccn1)S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 RDEMMWYBNGQWTB-UHFFFAOYSA-N 0.000 claims 1
- HRTWDOZWLFZJLM-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-(2-hydroxy-2-pyridazin-3-ylethyl)-N-methylbenzenesulfonamide Chemical compound CN(CC(O)c1cccnn1)S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 HRTWDOZWLFZJLM-UHFFFAOYSA-N 0.000 claims 1
- MLWRGQRWWSPOKA-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N(CCCO)CCO MLWRGQRWWSPOKA-UHFFFAOYSA-N 0.000 claims 1
- UKUHNUQWBQCUPR-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-(2-hydroxyethyl)benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)NCCO UKUHNUQWBQCUPR-UHFFFAOYSA-N 0.000 claims 1
- VVVAFAHCEMVGEF-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-(2-methylpyrazol-3-yl)benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C VVVAFAHCEMVGEF-UHFFFAOYSA-N 0.000 claims 1
- PEHMHVQIJBWODV-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-(3-morpholin-4-yl-3-oxopropyl)benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)NCCC(=O)N1CCOCC1 PEHMHVQIJBWODV-UHFFFAOYSA-N 0.000 claims 1
- NRJVECRBWGGEAM-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-(oxan-4-yl)benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)NC1CCOCC1 NRJVECRBWGGEAM-UHFFFAOYSA-N 0.000 claims 1
- LBCABJJXNNTYOJ-LLVKDONJSA-N 4-(6-fluoro-1H-indol-3-yl)-N-[(2R)-1-hydroxypropan-2-yl]benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N[C@@H](CO)C LBCABJJXNNTYOJ-LLVKDONJSA-N 0.000 claims 1
- LYTFOUQDGCCZCI-UONOGXRCSA-N 4-(6-fluoro-1H-indol-3-yl)-N-[(2S,3R)-3-hydroxybutan-2-yl]-N-(2-hydroxyethyl)benzenesulfonamide Chemical compound C[C@@H](O)[C@H](C)N(CCO)S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 LYTFOUQDGCCZCI-UONOGXRCSA-N 0.000 claims 1
- NGISXGQEOYEIDT-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)NCC1=NC(=NO1)C NGISXGQEOYEIDT-UHFFFAOYSA-N 0.000 claims 1
- XKXQHEYIRSUMLF-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-[(4-methyl-1,2,4-triazol-3-yl)methyl]benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)NCC1=NN=CN1C XKXQHEYIRSUMLF-UHFFFAOYSA-N 0.000 claims 1
- BAFJDLAAAMSRMA-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)NCC=1OC(=NN=1)C BAFJDLAAAMSRMA-UHFFFAOYSA-N 0.000 claims 1
- AEPHAJRJEPFLSG-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-[1-(4-methyl-1,2,4-triazol-3-yl)ethyl]benzenesulfonamide Chemical compound CC(NS(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12)c1nncn1C AEPHAJRJEPFLSG-UHFFFAOYSA-N 0.000 claims 1
- YNYCVJWDOJCRAI-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-[2-(1H-imidazol-2-yl)ethyl]benzenesulfonamide Chemical compound N1C(=NC=C1)CCNS(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(=CC=C12)F YNYCVJWDOJCRAI-UHFFFAOYSA-N 0.000 claims 1
- GLHXKUVDLGEMBN-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)NCCC1=NC(=NO1)C GLHXKUVDLGEMBN-UHFFFAOYSA-N 0.000 claims 1
- ONYONGSEXBKFND-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-[2-hydroxy-2-(1H-imidazol-2-yl)ethyl]-N-methylbenzenesulfonamide Chemical compound CN(CC(O)c1ncc[nH]1)S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 ONYONGSEXBKFND-UHFFFAOYSA-N 0.000 claims 1
- OTODPRHAZVYDNE-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]benzenesulfonamide Chemical compound CN1CCN(CC1)C(=O)CCNS(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 OTODPRHAZVYDNE-UHFFFAOYSA-N 0.000 claims 1
- NLBBEEVNDQBQBE-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-methyl-N-(2-sulfamoylethyl)benzenesulfonamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N(CCS(N)(=O)=O)C NLBBEEVNDQBQBE-UHFFFAOYSA-N 0.000 claims 1
- KYJJZPVLELWWBL-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)-N-methyl-N-[2-(methylsulfamoyl)ethyl]benzenesulfonamide Chemical compound CNS(=O)(=O)CCN(C)S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 KYJJZPVLELWWBL-UHFFFAOYSA-N 0.000 claims 1
- HWWGVHWIBZRKDC-UHFFFAOYSA-N 4-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(F)=CC=C12 HWWGVHWIBZRKDC-UHFFFAOYSA-N 0.000 claims 1
- YKLAXJDUZNMKEB-UHFFFAOYSA-N 4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-1,4-oxazepan-6-ol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CCOCC(C1)O YKLAXJDUZNMKEB-UHFFFAOYSA-N 0.000 claims 1
- CCVFZOPXQUCHPA-UHFFFAOYSA-N 4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-1-(2-hydroxyethyl)piperazin-2-one Chemical compound OCCN1CCN(CC1=O)S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 CCVFZOPXQUCHPA-UHFFFAOYSA-N 0.000 claims 1
- CYKCAHYQKFSPLP-UHFFFAOYSA-N 4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-1-[2-(methylamino)ethyl]piperazin-2-one Chemical compound CNCCN1CCN(CC1=O)S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 CYKCAHYQKFSPLP-UHFFFAOYSA-N 0.000 claims 1
- ORDCBYJERKSXBX-UHFFFAOYSA-N 4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-1-[3-(methylamino)propyl]piperazin-2-one Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CC(N(CC1)CCCNC)=O ORDCBYJERKSXBX-UHFFFAOYSA-N 0.000 claims 1
- FKRJNIXOGXSNDY-UHFFFAOYSA-N 4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-1-methylpiperazin-2-one Chemical compound CN1CCN(CC1=O)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(F)=CC=C12 FKRJNIXOGXSNDY-UHFFFAOYSA-N 0.000 claims 1
- RSZNQULXVIJVJA-UHFFFAOYSA-N 4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-1-methylpiperazine-2,6-dione Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CC(N(C(C1)=O)C)=O RSZNQULXVIJVJA-UHFFFAOYSA-N 0.000 claims 1
- VFQNXFRQJMGQJU-UHFFFAOYSA-N 4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylmorpholine Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CCOCC1 VFQNXFRQJMGQJU-UHFFFAOYSA-N 0.000 claims 1
- SMYQVFKLAAAPKU-UHFFFAOYSA-N 4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperazin-2-one Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CC(NCC1)=O SMYQVFKLAAAPKU-UHFFFAOYSA-N 0.000 claims 1
- LMRCSSPLWOKVGC-UHFFFAOYSA-N 4-[[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonyl-methylamino]butanamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N(C)CCCC(=O)N LMRCSSPLWOKVGC-UHFFFAOYSA-N 0.000 claims 1
- FWBDVIKJBWDAFE-UHFFFAOYSA-N 5-(6-fluoro-1H-indol-3-yl)-2-piperazin-1-ylsulfonylbenzonitrile Chemical compound FC1=CC=C2C(=CNC2=C1)C=1C=CC(=C(C#N)C=1)S(=O)(=O)N1CCNCC1 FWBDVIKJBWDAFE-UHFFFAOYSA-N 0.000 claims 1
- BAJVMZGPYPUFKM-UHFFFAOYSA-N 5-(6-fluoro-1H-indol-3-yl)-2-piperazin-1-ylsulfonylphenol Chemical compound FC1=CC=C2C(=CNC2=C1)C=1C=CC(=C(C=1)O)S(=O)(=O)N1CCNCC1 BAJVMZGPYPUFKM-UHFFFAOYSA-N 0.000 claims 1
- AQGYUKXHLHYMHX-UHFFFAOYSA-N 5-(6-fluoro-1H-indol-3-yl)-N-methyl-2-piperazin-1-ylsulfonylbenzamide Chemical compound FC1=CC=C2C(=CNC2=C1)C=1C=CC(=C(C(=O)NC)C=1)S(=O)(=O)N1CCNCC1 AQGYUKXHLHYMHX-UHFFFAOYSA-N 0.000 claims 1
- JQUVIYQWXAREMW-UHFFFAOYSA-N 6-fluoro-3-(2-fluoro-4-piperazin-1-ylsulfonylphenyl)-1H-indole Chemical compound Fc1ccc2c(c[nH]c2c1)-c1ccc(cc1F)S(=O)(=O)N1CCNCC1 JQUVIYQWXAREMW-UHFFFAOYSA-N 0.000 claims 1
- FMLSWWPWUZFILG-UHFFFAOYSA-N 6-fluoro-3-(2-methyl-4-piperazin-1-ylsulfonylphenyl)-1H-indole Chemical compound FC1=CC=C2C(=CNC2=C1)C1=C(C=C(C=C1)S(=O)(=O)N1CCNCC1)C FMLSWWPWUZFILG-UHFFFAOYSA-N 0.000 claims 1
- VFFFUKMZVQCYSI-UHFFFAOYSA-N 6-fluoro-3-(3-fluoro-4-piperazin-1-ylsulfonylphenyl)-1H-indole Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC(=C(C=C1)S(=O)(=O)N1CCNCC1)F VFFFUKMZVQCYSI-UHFFFAOYSA-N 0.000 claims 1
- BTMSWOMBMJJVQJ-UHFFFAOYSA-N 6-fluoro-3-(3-methoxy-4-piperazin-1-ylsulfonylphenyl)-1H-indole Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC(=C(C=C1)S(=O)(=O)N1CCNCC1)OC BTMSWOMBMJJVQJ-UHFFFAOYSA-N 0.000 claims 1
- VJGDGPWWHFOJDU-UHFFFAOYSA-N 6-fluoro-3-(3-methyl-4-piperazin-1-ylsulfonylphenyl)-1H-indole Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC(=C(C=C1)S(=O)(=O)N1CCNCC1)C VJGDGPWWHFOJDU-UHFFFAOYSA-N 0.000 claims 1
- IIYOEKXJEMFKPT-UHFFFAOYSA-N 6-fluoro-3-(3-methylsulfonylphenyl)-1H-indole Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC(=CC=C1)S(=O)(=O)C IIYOEKXJEMFKPT-UHFFFAOYSA-N 0.000 claims 1
- JKTPOXXPTJMAKP-UHFFFAOYSA-N 6-fluoro-3-(3-piperazin-1-ylsulfonylphenyl)-1H-indole Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCNCC1 JKTPOXXPTJMAKP-UHFFFAOYSA-N 0.000 claims 1
- AOFRJOAPTCXAIH-UHFFFAOYSA-N 6-fluoro-3-(4-methylsulfonylphenyl)-1H-indole Chemical compound CS(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 AOFRJOAPTCXAIH-UHFFFAOYSA-N 0.000 claims 1
- AFSAIXWLOFZVCZ-UHFFFAOYSA-N 6-fluoro-3-(4-piperazin-1-ylsulfonylphenyl)-1H-indole Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CCNCC1 AFSAIXWLOFZVCZ-UHFFFAOYSA-N 0.000 claims 1
- LXIUPELUVIEOAP-UHFFFAOYSA-N 6-fluoro-3-(4-piperazin-1-ylsulfonylphenyl)indole-1-carboxamide Chemical compound FC1=CC=C2C(=CN(C2=C1)C(=O)N)C1=CC=C(C=C1)S(=O)(=O)N1CCNCC1 LXIUPELUVIEOAP-UHFFFAOYSA-N 0.000 claims 1
- QPFCYKUCAYTYFB-UHFFFAOYSA-N 6-fluoro-3-[4-(4-methylsulfonylpiperazin-1-yl)sulfonylphenyl]-1H-indole Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)S(=O)(=O)C QPFCYKUCAYTYFB-UHFFFAOYSA-N 0.000 claims 1
- RJVXRDFICMBGJO-UHFFFAOYSA-N 6-fluoro-3-[4-piperazin-1-ylsulfonyl-3-(trifluoromethyl)phenyl]-1H-indole Chemical compound Fc1ccc2c(c[nH]c2c1)-c1ccc(c(c1)C(F)(F)F)S(=O)(=O)N1CCNCC1 RJVXRDFICMBGJO-UHFFFAOYSA-N 0.000 claims 1
- GLDUUZZGTJPZPP-UHFFFAOYSA-N 6-fluoro-N,N-dimethyl-3-(4-piperazin-1-ylsulfonylphenyl)indole-1-carboxamide Chemical compound FC1=CC=C2C(=CN(C2=C1)C(=O)N(C)C)C1=CC=C(C=C1)S(=O)(=O)N1CCNCC1 GLDUUZZGTJPZPP-UHFFFAOYSA-N 0.000 claims 1
- JAOXNFDTBYGYFK-UHFFFAOYSA-N 6-fluoro-N-methyl-3-(4-piperazin-1-ylsulfonylphenyl)indole-1-carboxamide Chemical compound FC1=CC=C2C(=CN(C2=C1)C(=O)NC)C1=CC=C(C=C1)S(=O)(=O)N1CCNCC1 JAOXNFDTBYGYFK-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 1
- IIXDDJGDNPGPOO-UHFFFAOYSA-N N-(2-aminoethyl)-2-chloro-5-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound NCCNS(=O)(=O)C1=C(C=CC(=C1)C1=CNC2=CC(=CC=C12)F)Cl IIXDDJGDNPGPOO-UHFFFAOYSA-N 0.000 claims 1
- CJKJZKSGLJMVQJ-UHFFFAOYSA-N N-(2-aminoethyl)-2-fluoro-5-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound NCCNS(=O)(=O)C1=C(C=CC(=C1)C1=CNC2=CC(=CC=C12)F)F CJKJZKSGLJMVQJ-UHFFFAOYSA-N 0.000 claims 1
- RVMMJVXNRQPJGB-UHFFFAOYSA-N N-(2-aminoethyl)-3-(6-fluoro-1H-indol-3-yl)-5-methylbenzenesulfonamide Chemical compound NCCNS(=O)(=O)C1=CC(=CC(=C1)C)C1=CNC2=CC(=CC=C12)F RVMMJVXNRQPJGB-UHFFFAOYSA-N 0.000 claims 1
- IUFCTGIECHPIMF-UHFFFAOYSA-N N-(2-aminoethyl)-3-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound NCCNS(=O)(=O)c1cccc(c1)-c1c[nH]c2cc(F)ccc12 IUFCTGIECHPIMF-UHFFFAOYSA-N 0.000 claims 1
- GGJKTJXGBQINMV-UHFFFAOYSA-N N-(2-aminoethyl)-3-chloro-5-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound NCCNS(=O)(=O)C1=CC(=CC(=C1)C1=CNC2=CC(=CC=C12)F)Cl GGJKTJXGBQINMV-UHFFFAOYSA-N 0.000 claims 1
- IPFWGGVIVVXCNO-UHFFFAOYSA-N N-(2-aminoethyl)-3-fluoro-5-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound NCCNS(=O)(=O)C1=CC(=CC(=C1)C1=CNC2=CC(=CC=C12)F)F IPFWGGVIVVXCNO-UHFFFAOYSA-N 0.000 claims 1
- JJOVHEKCKOXFSE-UHFFFAOYSA-N N-(2-aminoethyl)-4-(6-fluoro-1H-indol-3-yl)benzamide Chemical compound NCCNC(C1=CC=C(C=C1)C1=CNC2=CC(=CC=C12)F)=O JJOVHEKCKOXFSE-UHFFFAOYSA-N 0.000 claims 1
- NORSHIICCPKYMZ-UHFFFAOYSA-N N-(2-aminoethyl)-4-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound NCCNS(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(=CC=C12)F NORSHIICCPKYMZ-UHFFFAOYSA-N 0.000 claims 1
- LZTAQAVJCXPHDG-UHFFFAOYSA-N N-(2-aminoethyl)-4-fluoro-3-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound NCCNS(=O)(=O)C1=CC(=C(C=C1)F)C1=CNC2=CC(=CC=C12)F LZTAQAVJCXPHDG-UHFFFAOYSA-N 0.000 claims 1
- XGFHAGLFQXFXOF-UHFFFAOYSA-N N-(2-aminoethyl)-5-(6-fluoro-1H-indol-3-yl)-2-hydroxybenzenesulfonamide Chemical compound NCCNS(=O)(=O)C1=C(C=CC(=C1)C1=CNC2=CC(=CC=C12)F)O XGFHAGLFQXFXOF-UHFFFAOYSA-N 0.000 claims 1
- AFCAKKSBUZZDHV-UHFFFAOYSA-N N-(2-aminoethyl)-5-(6-fluoro-1H-indol-3-yl)-2-methylbenzenesulfonamide Chemical compound NCCNS(=O)(=O)C1=C(C=CC(=C1)C1=CNC2=CC(=CC=C12)F)C AFCAKKSBUZZDHV-UHFFFAOYSA-N 0.000 claims 1
- OOXUNMAPHDHZPU-UHFFFAOYSA-N N-(azetidin-3-yl)-4-(6-fluoro-1H-indol-3-yl)benzenesulfonamide Chemical compound N1CC(C1)NS(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(=CC=C12)F OOXUNMAPHDHZPU-UHFFFAOYSA-N 0.000 claims 1
- ZJKHKPIKVPYNCU-UHFFFAOYSA-N N-[2-[[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylamino]ethyl]-4-methylpiperazine-1-carboxamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)NCCNC(=O)N1CCN(CC1)C ZJKHKPIKVPYNCU-UHFFFAOYSA-N 0.000 claims 1
- SVKRQNPEINDMMK-UHFFFAOYSA-N N-[2-[[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylamino]ethyl]acetamide Chemical compound CC(=O)NCCNS(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 SVKRQNPEINDMMK-UHFFFAOYSA-N 0.000 claims 1
- RLVGOAORLZNWSM-UHFFFAOYSA-N N-[2-[[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylamino]ethyl]morpholine-4-carboxamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)NCCNC(=O)N1CCOCC1 RLVGOAORLZNWSM-UHFFFAOYSA-N 0.000 claims 1
- YVNVMOUXOFIYOD-UHFFFAOYSA-N N-[2-[[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylamino]ethyl]piperazine-1-carboxamide Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)NCCNC(=O)N1CCNCC1 YVNVMOUXOFIYOD-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- PQDMOLAPORBHDQ-OAHLLOKOSA-N [(2R)-4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperazin-2-yl]methanol Chemical compound OC[C@H]1CN(CCN1)S(=O)(=O)c1ccc(cc1)-c1c[nH]c2cc(F)ccc12 PQDMOLAPORBHDQ-OAHLLOKOSA-N 0.000 claims 1
- PQDMOLAPORBHDQ-HNNXBMFYSA-N [(2S)-4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperazin-2-yl]methanol Chemical compound OC[C@@H]1CN(CCN1)S(=O)(=O)C1=CC=C(C=C1)C1=CNC2=CC(F)=CC=C12 PQDMOLAPORBHDQ-HNNXBMFYSA-N 0.000 claims 1
- LYNAFYOHYQXREF-OAHLLOKOSA-N [(3R)-4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylmorpholin-3-yl]methanol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1[C@@H](COCC1)CO LYNAFYOHYQXREF-OAHLLOKOSA-N 0.000 claims 1
- LYNAFYOHYQXREF-HNNXBMFYSA-N [(3S)-4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylmorpholin-3-yl]methanol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1[C@H](COCC1)CO LYNAFYOHYQXREF-HNNXBMFYSA-N 0.000 claims 1
- KUXMPXRXMRCHGD-UHFFFAOYSA-N [1-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylazetidin-3-yl]methanol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CC(C1)CO KUXMPXRXMRCHGD-UHFFFAOYSA-N 0.000 claims 1
- CDMDFPFWGCQBGZ-UHFFFAOYSA-N [4-(6-fluoro-1H-indol-3-yl)phenyl]-piperazin-1-ylmethanone Chemical compound FC1=CC=C2C(NC=C2C2=CC=C(C=C2)C(=O)N2CCNCC2)=C1 CDMDFPFWGCQBGZ-UHFFFAOYSA-N 0.000 claims 1
- PQDMOLAPORBHDQ-UHFFFAOYSA-N [4-[4-(6-fluoro-1H-indol-3-yl)phenyl]sulfonylpiperazin-2-yl]methanol Chemical compound FC1=CC=C2C(=CNC2=C1)C1=CC=C(C=C1)S(=O)(=O)N1CC(NCC1)CO PQDMOLAPORBHDQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- VALZSZJVEFACEZ-UHFFFAOYSA-N azetidine-3-carboxamide Chemical compound NC(=O)C1CNC1 VALZSZJVEFACEZ-UHFFFAOYSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203032P | 2015-08-10 | 2015-08-10 | |
| US62/203,032 | 2015-08-10 | ||
| US201662309530P | 2016-03-17 | 2016-03-17 | |
| US62/309,530 | 2016-03-17 | ||
| PCT/IB2016/054701 WO2017025868A1 (en) | 2015-08-10 | 2016-08-04 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018527336A JP2018527336A (ja) | 2018-09-20 |
| JP2018527336A5 true JP2018527336A5 (enExample) | 2019-09-05 |
Family
ID=56801656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506432A Ceased JP2018527336A (ja) | 2015-08-10 | 2016-08-04 | ３−インドール置換誘導体、医薬組成物、および使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10544095B2 (enExample) |
| EP (1) | EP3334733A1 (enExample) |
| JP (1) | JP2018527336A (enExample) |
| CA (1) | CA2994917A1 (enExample) |
| WO (1) | WO2017025868A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017011951A (es) * | 2015-03-17 | 2018-06-15 | Pfizer | Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso. |
| MX383614B (es) | 2015-05-21 | 2025-03-14 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
| WO2017197240A1 (en) * | 2016-05-12 | 2017-11-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3269714A1 (en) * | 2016-07-13 | 2018-01-17 | Netherlands Translational Research Center B.V. | Inhibitors of tryptophan 2,3-dioxygenase |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| CN110891974B (zh) | 2017-05-12 | 2021-08-06 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
| CN108948002A (zh) * | 2017-05-19 | 2018-12-07 | 厦门大学 | 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用 |
| EP3630842A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| PE20201183A1 (es) | 2017-10-13 | 2020-11-03 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US10632209B2 (en) * | 2017-11-10 | 2020-04-28 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| CN108794376B (zh) * | 2018-04-28 | 2021-01-05 | 北京施安泰医药技术开发有限公司 | 甲酰胺类衍生物、其药物组合物、制备方法与用途 |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| KR20230004458A (ko) * | 2020-02-27 | 2023-01-06 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Apc-결핍 암의 치료를 위한 방법 및 조성물 |
| CN111825678A (zh) * | 2020-06-05 | 2020-10-27 | 连庆泉 | 一种卡马替尼的制备方法 |
| CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| EP4370552A1 (en) | 2021-07-13 | 2024-05-22 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| CN119156403A (zh) | 2022-03-08 | 2024-12-17 | 阿伦蒂斯治疗股份公司 | 抗紧密连接蛋白-1抗体增加t细胞可用性的用途 |
| KR20250120305A (ko) | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509731C2 (sv) | 1996-05-14 | 1999-03-01 | Labwell Ab | Metod för palladium-katalyserade organiska reaktioner innefattande ett uppvärmningssteg utfört med mikrovågsenergi |
| JP2000095759A (ja) | 1998-07-21 | 2000-04-04 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および剤 |
| US6265403B1 (en) | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
| WO2003035625A1 (en) | 2001-09-19 | 2003-05-01 | Pharmacia Corporation | Substituted indazole compounds for the treatment of inflammation |
| CA2479205A1 (en) | 2002-03-28 | 2003-10-09 | Eisai Co., Ltd. | Azaindoles as inhibitors of c-jun n-terminal kinases |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| FR2845996A1 (fr) | 2002-10-16 | 2004-04-23 | Servier Lab | Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN101265254A (zh) | 2003-03-27 | 2008-09-17 | 兰肯瑙医学研究所 | 新型ido抑制剂及其使用方法 |
| FR2862647B1 (fr) | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
| GB0328909D0 (en) | 2003-12-12 | 2004-01-14 | Syngenta Participations Ag | Chemical compounds |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| HRP20100650T2 (hr) | 2005-02-09 | 2012-02-29 | Arqule | Derivati maleimida, farmaceutski pripravci i postupci liječenja raka |
| WO2007039580A1 (en) | 2005-10-05 | 2007-04-12 | Nycomed Gmbh | Imidazolyl-substituted benzophenone compounds |
| WO2007045622A1 (en) | 2005-10-18 | 2007-04-26 | Nycomed Gmbh | Oxazolo [4 , 5-b] pyridine compounds as nitric oxide synthase inhibitors |
| WO2007050963A1 (en) | 2005-10-27 | 2007-05-03 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use thereof |
| AU2007208109B2 (en) | 2006-01-24 | 2012-08-23 | Eli Lilly And Company | Indole sulfonamide modulators of progesterone receptors |
| MX2008012482A (es) | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
| CN101415409B (zh) | 2006-04-05 | 2012-12-05 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| GB0624308D0 (en) | 2006-12-05 | 2007-01-17 | Molmed Spa | Combination product |
| RU2009125620A (ru) | 2006-12-07 | 2011-01-20 | Новартис АГ (CH) | Органические соединения |
| CA2677096A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| EP2137168B1 (en) | 2007-03-16 | 2016-09-14 | Lankenau Institute for Medical Research | Novel ido inhibitors and methods of use thereof |
| EP2183217A2 (en) | 2007-07-25 | 2010-05-12 | Boehringer Ingelheim International GmbH | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| AU2008331480A1 (en) | 2007-11-30 | 2009-06-11 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| EP2268612B1 (en) * | 2008-03-24 | 2014-08-20 | Novartis AG | Arylsulfonamide-based matrix metalloprotease inhibitors |
| US20110159017A1 (en) | 2008-04-11 | 2011-06-30 | Ludwig Institute For Cancer Research Ltd. | Trytophan catabolism in cancer treatment and diagnosis |
| DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
| MX2011008645A (es) | 2009-02-17 | 2011-09-30 | Vertex Pharma | Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa. |
| WO2010136491A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| CA2668905A1 (en) * | 2009-06-15 | 2010-12-15 | University Of Saskatchewan | Method for inhibiting brassinin oxidase |
| KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| JP5791612B2 (ja) | 2009-09-23 | 2015-10-07 | メディベイション テクノロジーズ， インコーポレイテッド | ピリド［３，４−ｂ］インドールおよび使用方法 |
| ES2533798T3 (es) | 2009-10-12 | 2015-04-14 | Bayer Cropscience Ag | 1-(pirid-3-il)-pirazol y 1-(pirimid-5-il)- pirazol como agentes para combatir parásitos |
| KR101804588B1 (ko) | 2009-10-13 | 2017-12-04 | 리간드 파마슈티칼스 인코포레이티드 | 조혈 성장 인자 모방체 소분자 화합물 및 이의 용도 |
| EP2642994A2 (en) | 2010-11-18 | 2013-10-02 | Ligand Pharmaceuticals Incorporated | Use of hematopoietic growth factor mimetics |
| JP2014510105A (ja) | 2011-03-22 | 2014-04-24 | アムジエン・インコーポレーテツド | Ｐｉｍ阻害剤としてのアゾール化合物 |
| LT2714677T (lt) | 2011-05-23 | 2018-12-10 | Merck Patent Gmbh | Piridino ir pirazino dariniai |
| JP2014521749A (ja) | 2011-08-17 | 2014-08-28 | アムジエン・インコーポレーテツド | ヘテロアリールナトリウムチャネル阻害剤 |
| US20160263087A1 (en) | 2013-11-08 | 2016-09-15 | Iteos Therapeutics | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US9126984B2 (en) | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US9931347B2 (en) * | 2013-12-03 | 2018-04-03 | Iomet Pharma Ltd. | Pharmaceutical compound |
| EP3105225A1 (en) | 2014-02-12 | 2016-12-21 | iTeos Therapeutics | Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use |
| US20150266857A1 (en) | 2014-03-18 | 2015-09-24 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| EP3119763A1 (en) | 2014-03-18 | 2017-01-25 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| WO2015173764A1 (en) | 2014-05-15 | 2015-11-19 | Iteos Therapeutics | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors |
| EP3269714A1 (en) * | 2016-07-13 | 2018-01-17 | Netherlands Translational Research Center B.V. | Inhibitors of tryptophan 2,3-dioxygenase |
-
2016
- 2016-08-04 WO PCT/IB2016/054701 patent/WO2017025868A1/en not_active Ceased
- 2016-08-04 EP EP16757354.2A patent/EP3334733A1/en not_active Withdrawn
- 2016-08-04 CA CA2994917A patent/CA2994917A1/en not_active Abandoned
- 2016-08-04 US US15/749,963 patent/US10544095B2/en active Active
- 2016-08-04 JP JP2018506432A patent/JP2018527336A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018527336A5 (enExample) | ||
| RU2455288C2 (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| RU2469032C2 (ru) | Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы | |
| JP2018511587A5 (enExample) | ||
| JP2013510876A5 (enExample) | ||
| RU2697665C1 (ru) | Производные 1,3,4-оксадиазолсульфонамида в качестве ингибиторов деацетилазы гистонов 6 и фармацевтическая композиция, содержащая их | |
| JP2007519754A5 (enExample) | ||
| RU2436776C2 (ru) | ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT | |
| JP2022043059A5 (enExample) | ||
| CA2601508A1 (en) | Cyclopropanecarboxamide derivatives | |
| JP2016510035A5 (enExample) | ||
| NZ599778A (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
| RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2013507449A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| MX2010006260A (es) | Composiciones orales de abt-263 para tratar cancer. | |
| RU2006126974A (ru) | Амидное производное и лекарственное средство | |
| CA2478068A1 (en) | Dihydropyrazole compounds useful for treating or preventing cancer | |
| WO2017025868A1 (en) | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | |
| JP2010504280A5 (enExample) | ||
| JP2013512900A5 (enExample) | ||
| JP2008517945A5 (enExample) | ||
| RU2009137363A (ru) | Соединения фениламинопиримидина и их применения | |
| RU2012127790A (ru) | Индуцирующие апоптоз агенты для лечения рака и иммунных и аутоиммунных заболеваний | |
| IL291590B2 (en) | Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof |